NGM Bio closes in on $51M to treat metabolic diseases
NGM Biopharmaceuticals, a medical startup looking to treat metabolic disorders like type 2 diabetes, has brought in an undisclosed amount of capital toward its goal of a $51 million second round of funding. Based in South San Francisco, the company is backed by the Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.
Next Story: Zynga recruits Electronic Arts veteran to run game studios
Previous Story: Counsyl bags $2.2M for pre-natal genetic testing
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
